U.K. to Pilot Illumina Genetic Test for Breast, Ovarian Cancer - Bloomberg

 Bloomberg

The U.K. is piloting a new genetic test developed by Illumina Inc. (ILMN) to help cancer patients and their doctors better identify appropriate treatments and help determine if relatives have cancer risk.
Illumina’s TruSight test, to be introduced in 2014 at the Royal Marsden hospitals in London and Sutton, can analyze 97 genes that are linked to cancer within a few weeks for a few hundred dollars, the Wellcome Trust said in a statement today. The pilot program will start for women with breast and ovarian cancer and may eventually be rolled out to the rest of the U.K. National Health Service and for other types of cancers, it said......